

**Meeting of the  
Connecticut Health Care Cabinet Work Group  
on Pharmaceutical Drug Cost Determination and Cost Containment  
Sept. 11, 2017  
3:00 PM – 5:00 PM  
Conference Room 2A  
Office of the Health Care Advocate  
450 Capitol Ave., Hartford  
Call in: 1 (646) 876-9923  
Meeting ID: 398 386 733**

**AGENDA**

**Meeting Goals:**

- To complete the discussion on transparency begun on August 29<sup>th</sup>:
  - To understand the various supply chain transparency issues as they differ from Pharma transparency.
  - To begin clarifying where states are intervening to achieve greater transparency.
  - To begin identifying possible data needs to inform future recommendations.

**1. Public Comment**

- 2. Pharma Transparency: What information are some states requiring or considering requiring of the pharmaceutical industry, and with what challenges? What questions do we want to ask of the Yale University researchers presenting at the Sept. 12<sup>th</sup> Health Care Cabinet meeting?**

See:

- a. *Curbing Unfair Drug Prices, A Primer for States*  
Yale University Global Health Justice Partnership Policy Paper, August 2017  
<https://universalhealthct.files.wordpress.com/2017/08/curbing-unfair-drug-prices-policy-paper-080717.pdf> (especially pp.7-8, 14 -17)
- b. *States and the Rising Cost of Pharmaceuticals: A Call to Action*  
National Academy for State Health Policy's Pharmacy Cost Work Group, October 2016  
<http://nashp.org/wp-content/uploads/2016/10/Rx-Paper.pdf> (especially pp. 7-8)
  - c. Las Vegas Review Journal: <https://www.reviewjournal.com/crime/courts/lawsuit-challenges-nevadas-new-diabetes-drug-disclosure-law/>

- 3. Supply Chain Transparency: Is there anything from the last discussion that should be taken up further? What points in the Rx Supply Chain chart require further examination?**

See:

- a. "Rx Pricing Along the Supply Chain" slide by the Altarum Institute Value Care Hub (attached)
- b. "The Prescription Drug Supply Chain 'Black Box': How it Works and Why You Should Care" by Henry C. Eickelberg, for the American Health Policy Institute  
[http://www.americanhealthpolicy.org/Content/documents/resources/December%202015\\_AHPI%20Study\\_Understanding\\_the\\_Pharma\\_Black\\_Box.pdf](http://www.americanhealthpolicy.org/Content/documents/resources/December%202015_AHPI%20Study_Understanding_the_Pharma_Black_Box.pdf)

**4. Major Takeaways**

a. What are some of the data needs emerging for our group's work?

5. **Next steps**